Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

被引:566
作者
Knudsen, LB
Nielsen, PF
Huusfeldt, PO
Johansen, NL
Madsen, K
Pedersen, FZ
Thogersen, H
Wilken, M
Agerso, H
机构
[1] Novo Nordisk AS, Hlth Care Discovery & Preclin Dev, Dept Mol Pharmacol, DK-2760 Maaloev, Denmark
[2] Novo Nordisk AS, Hlth Care Discovery & Preclin Dev, Dept Prot Chem, DK-2760 Maaloev, Denmark
[3] Novo Nordisk AS, Hlth Care Discovery & Preclin Dev, Dept Med Chem, DK-2760 Maaloev, Denmark
[4] Novo Nordisk AS, Hlth Care Discovery & Preclin Dev, Dept Assay & Cell Technol, DK-2760 Maaloev, Denmark
[5] Novo Nordisk AS, Hlth Care Discovery & Preclin Dev, Dept Pharmacokinet, DK-2760 Maaloev, Denmark
关键词
D O I
10.1021/jm9909645
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of very potent derivatives of the 30-amino acid peptide hormone glucagon-like peptide-1 (GLP-1) is described. The compounds were all derivatized with fatty acids in order to protract their action by facilitating binding to serum albumin. GLP-1 had a potency (EC50 of 55 pM for the cloned human GLP-1 receptor. Many of the compounds had similar or even higher potencies, despite quite large substituents. All compounds derivatized with fatty acids equal to or longer than 12 carbon atoms were very protracted compared to GLP-1 and thus seem suitable for once daily administration to type 2 diabetic patients. A structure-activity relationship was obtained. GLP-1 could be derivatized with linear fatty acids up to the length of 16 carbon atoms, sometimes longer, almost anywhere in the C-terminal part without considerable loss of potency. Derivatization with two fatty acid substituents led to a considerable loss of potency. A structure-activity relationship on derivatization of specific amino acids generally was obtained. It was found that the longer the fatty acid, the more potency was lost. Simultaneous modification of the N-terminus tin order to obtain better metabolic stability) interfered with fatty acid derivatization and led to loss of potency.
引用
收藏
页码:1664 / 1669
页数:6
相关论文
共 33 条
  • [1] ADELHORST K, 1994, J BIOL CHEM, V269, P6275
  • [2] BUCKLEY DI, Patent No. 5545618
  • [3] CHEN VJ, Patent No. 5512549
  • [4] Effects of non-covalent self-association on the subcutaneous absorption of a therapeutic peptide
    Clodfelter, DK
    Pekar, AH
    Rebhun, DM
    Destrampe, KA
    Havel, HA
    Myers, SR
    Brader, ML
    [J]. PHARMACEUTICAL RESEARCH, 1998, 15 (02) : 254 - 262
  • [5] Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity
    Deacon, CF
    Knudsen, LB
    Madsen, K
    Wiberg, FC
    Jacobsen, O
    Holst, JJ
    [J]. DIABETOLOGIA, 1998, 41 (03) : 271 - 278
  • [6] DEGRADATION OF GLUCAGON-LIKE PEPTIDE-1 BY HUMAN PLASMA IN-VITRO YIELDS AN N-TERMINALLY TRUNCATED PEPTIDE THAT IS A MAJOR ENDOGENOUS METABOLITE IN-VIVO
    DEACON, CF
    JOHNSEN, AH
    HOLST, JJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (03) : 952 - 957
  • [7] EBASHI I, Patent No. 511600
  • [8] Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?)
    Edvell, A
    Lindström, P
    [J]. ENDOCRINOLOGY, 1999, 140 (02) : 778 - 783
  • [9] Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans
    Flint, A
    Raben, A
    Astrup, A
    Holst, JJ
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (03) : 515 - 520
  • [10] SUBCUTANEOUS INJECTION OF THE INCRETIN HORMONE GLUCAGON-LIKE PEPTIDE-1 ABOLISHES POSTPRANDIAL GLYCEMIA IN NIDDM
    GUTNIAK, MK
    LINDE, B
    HOLST, JJ
    EFENDIC, S
    [J]. DIABETES CARE, 1994, 17 (09) : 1039 - 1044